Document is current
Any future updates will be listed below
-
Authors
Mouhieddine, Tarek H. https://orcid.org/0000-0002-1190-5978
Sperling, Adam S.
Redd, Robert https://orcid.org/0000-0002-1329-5288
Park, Jihye
Leventhal, Matthew
Gibson, Christopher J.
Manier, Salomon
Nassar, Amin H. https://orcid.org/0000-0002-8084-9105
Capelletti, Marzia
Huynh, Daisy
Bustoros, Mark https://orcid.org/0000-0002-4652-5449
Sklavenitis-Pistofidis, Romanos
Tahri, Sabrin
Hornburg, Kalvis
Dumke, Henry
Itani, Muhieddine M.
Boehner, Cody J.
Liu, Chia-Jen https://orcid.org/0000-0001-7945-9292
AlDubayan, Saud H.
Reardon, Brendan
Van Allen, Eliezer M.
Keats, Jonathan J. https://orcid.org/0000-0003-4375-7399
Stewart, Chip
Mehr, Shaadi
Auclair, Daniel
Schlossman, Robert L.
Munshi, Nikhil C.
Anderson, Kenneth C.
Steensma, David P. https://orcid.org/0000-0001-5130-9284
Laubach, Jacob P.
Richardson, Paul G.
Ritz, Jerome https://orcid.org/0000-0001-5526-4669
Ebert, Benjamin L. https://orcid.org/0000-0003-0197-5451
Soiffer, Robert J.
Trippa, Lorenzo
Getz, Gad https://orcid.org/0000-0002-0936-0753
Neuberg, Donna S.
Ghobrial, Irene M. https://orcid.org/0000-0001-7361-3092
-
Funding
Funding for this research was provided by:
Multiple Myeloma Research Foundation
Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
EIF | Stand Up To Cancer
Leukemia and Lymphoma Society
- License Information
-
More Information
Article History
Received: 9 January 2020
Accepted: 20 May 2020
First Online: 12 June 2020
Competing interests
: The authors declare the following competing interests: M.B.: Dava Oncology: Honoraria. N.C.M.: OncoPep: Other: Board of director. K.C.A.: Gilead: Membership on an entity’s Board of Directors or advisory committees; OncoPep: Equity Ownership, Scientific founder; Celgene: Consultancy; C4 Therapeutics: Equity Ownership, Scientific founder; Bristol Myers Squibb: Consultancy; Millennium Takeda: Consultancy. P.G.R.: Oncopeptides: Membership on an entity’s Board of Directors or advisory committees; BMS: Research Funding; Janssen: Membership on an entity’s Board of Directors or advisory committees; Karyopharm: Membership on an entity’s Board of Directors or advisory committees; Jazz Pharmaceuticals: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Celgene: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Amgen: Membership on an entity’s Board of Directors or advisory committees; Takeda: Membership on an entity’s Board of Directors or advisory committees, Research Funding. Amgen: Research Funding; Equillium: Research Funding; Kite/Gilead: Research Funding; Aleta Biotherapeutics: Consultancy; Avrobio: Consultancy; Celgene: Consultancy; Falcon Therapeutics: Consultancy; Talaris Therapeutics: Consultancy; TScan Therapuetics: Consultancy. B.L.E.: Celgene: Research funding; Deerfield: Research funding; GRAIL: Consultancy; Exo Therapeutics: scientific advisory boards; Skyhawk Therapeutics: scientific advisory boards. R.J.S.: Kiadis: Board of Directors; Juno: DSMB; Gilead: Consultancy; Neovii: Consultancy; Cugene: Consultancy; Jazz: Consultancy; Mana Therapeutics: Consultancy; VOR: Consultancy; Novartis: Consultancy. G.G.: receives research funds from IBM and Pharmacyclics and is an inventor on patent applications related to MuTect, ABSOLUTE, MutSig and POLYSOLVER. I.M.G.: Celgene: Consultancy; Janssen: Consultancy; BMS: Consultancy; Takeda: Consultancy; GSK: Consultancy; Sanofi: Consultancy; Karyopharm: Consultancy; Abbvie: Consultancy; Cellectar: Consultancy; Genentech: Consultancy; Adaptive: Consultancy. The remaining authors declare no competing interests.
